| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stomach Neoplasms | 60 | 2024 | 2324 | 4.020 |
Why?
|
| Adenocarcinoma | 44 | 2023 | 7909 | 2.190 |
Why?
|
| Neuroendocrine Tumors | 11 | 2024 | 652 | 1.890 |
Why?
|
| Pancreatic Neoplasms | 18 | 2024 | 5251 | 1.460 |
Why?
|
| Peritoneal Neoplasms | 13 | 2024 | 855 | 1.180 |
Why?
|
| Gastrectomy | 17 | 2024 | 476 | 0.980 |
Why?
|
| Esophagogastric Junction | 9 | 2021 | 557 | 0.970 |
Why?
|
| Pancreaticoduodenectomy | 6 | 2019 | 706 | 0.890 |
Why?
|
| Lymph Nodes | 13 | 2021 | 3072 | 0.860 |
Why?
|
| Esophageal Neoplasms | 12 | 2021 | 3240 | 0.830 |
Why?
|
| Hyperthermia, Induced | 6 | 2024 | 511 | 0.740 |
Why?
|
| Carcinoma, Pancreatic Ductal | 7 | 2020 | 1826 | 0.730 |
Why?
|
| Immunohistochemistry | 11 | 2020 | 7663 | 0.680 |
Why?
|
| Neoplasms, Unknown Primary | 4 | 2023 | 199 | 0.660 |
Why?
|
| Chemoradiotherapy | 11 | 2021 | 2027 | 0.630 |
Why?
|
| Neoadjuvant Therapy | 21 | 2023 | 5225 | 0.610 |
Why?
|
| Adenoma | 2 | 2014 | 739 | 0.590 |
Why?
|
| Intestinal Neoplasms | 2 | 2020 | 203 | 0.560 |
Why?
|
| Lymph Node Excision | 8 | 2021 | 2056 | 0.500 |
Why?
|
| Neoplasm Staging | 27 | 2021 | 14003 | 0.500 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2015 | 48 | 0.490 |
Why?
|
| Biomarkers, Tumor | 10 | 2021 | 10699 | 0.480 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 2023 | 333 | 0.470 |
Why?
|
| Middle Aged | 61 | 2021 | 90192 | 0.460 |
Why?
|
| Preoperative Care | 8 | 2021 | 1552 | 0.460 |
Why?
|
| Aged | 56 | 2021 | 73248 | 0.430 |
Why?
|
| Lymphatic Metastasis | 10 | 2021 | 4957 | 0.430 |
Why?
|
| Pancreas | 3 | 2015 | 744 | 0.410 |
Why?
|
| Intestinal Mucosa | 3 | 2020 | 1105 | 0.410 |
Why?
|
| Survival Rate | 23 | 2024 | 12509 | 0.400 |
Why?
|
| Male | 68 | 2021 | 128209 | 0.400 |
Why?
|
| Carcinoma, Signet Ring Cell | 3 | 2020 | 180 | 0.400 |
Why?
|
| Female | 70 | 2021 | 148723 | 0.400 |
Why?
|
| Kaplan-Meier Estimate | 15 | 2021 | 6253 | 0.390 |
Why?
|
| Retrospective Studies | 38 | 2024 | 39760 | 0.380 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2015 | 1327 | 0.380 |
Why?
|
| Prognosis | 28 | 2023 | 22466 | 0.370 |
Why?
|
| Humans | 96 | 2024 | 270462 | 0.370 |
Why?
|
| Colorectal Neoplasms | 3 | 2015 | 3707 | 0.370 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 556 | 0.360 |
Why?
|
| Bile Duct Neoplasms | 3 | 2023 | 500 | 0.360 |
Why?
|
| Cholangiocarcinoma | 3 | 2023 | 503 | 0.360 |
Why?
|
| beta Catenin | 1 | 2014 | 682 | 0.360 |
Why?
|
| Chemoradiotherapy, Adjuvant | 8 | 2020 | 562 | 0.360 |
Why?
|
| Aged, 80 and over | 32 | 2021 | 30976 | 0.350 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2016 | 624 | 0.350 |
Why?
|
| Laparoscopy | 6 | 2019 | 1301 | 0.340 |
Why?
|
| Adult | 43 | 2021 | 81851 | 0.340 |
Why?
|
| Receptors, Progesterone | 2 | 2014 | 1603 | 0.330 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2023 | 10382 | 0.330 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 1012 | 0.320 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 3 | 2020 | 182 | 0.320 |
Why?
|
| Down-Regulation | 1 | 2014 | 2091 | 0.320 |
Why?
|
| Linitis Plastica | 2 | 2019 | 12 | 0.320 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2013 | 496 | 0.310 |
Why?
|
| Cat Diseases | 1 | 2007 | 17 | 0.300 |
Why?
|
| Esophagus | 1 | 2011 | 562 | 0.300 |
Why?
|
| Capillaries | 1 | 2007 | 98 | 0.300 |
Why?
|
| Adaptor Proteins, Signal Transducing | 5 | 2022 | 1469 | 0.290 |
Why?
|
| Peripheral Nerves | 1 | 2007 | 160 | 0.290 |
Why?
|
| Gastric Mucosa | 1 | 2011 | 660 | 0.280 |
Why?
|
| Diabetic Neuropathies | 1 | 2007 | 92 | 0.280 |
Why?
|
| Follow-Up Studies | 15 | 2021 | 15188 | 0.270 |
Why?
|
| Adenomatous Polyposis Coli | 2 | 2020 | 226 | 0.260 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2024 | 98 | 0.260 |
Why?
|
| Neoplasm Grading | 6 | 2017 | 1822 | 0.260 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 3344 | 0.260 |
Why?
|
| Disease-Free Survival | 12 | 2020 | 10258 | 0.260 |
Why?
|
| Carcinogenesis | 3 | 2022 | 1033 | 0.250 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 5309 | 0.230 |
Why?
|
| Liver Neoplasms | 3 | 2021 | 4815 | 0.230 |
Why?
|
| Texas | 7 | 2021 | 6433 | 0.230 |
Why?
|
| Mesenteric Artery, Superior | 2 | 2015 | 77 | 0.220 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 879 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 5 | 2021 | 4044 | 0.220 |
Why?
|
| Combined Modality Therapy | 11 | 2024 | 9039 | 0.220 |
Why?
|
| Proportional Hazards Models | 9 | 2021 | 5099 | 0.220 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2018 | 3993 | 0.220 |
Why?
|
| Islets of Langerhans | 2 | 2022 | 236 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2024 | 16640 | 0.210 |
Why?
|
| Tumor Burden | 4 | 2015 | 2033 | 0.200 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2020 | 2616 | 0.190 |
Why?
|
| Diagnosis, Differential | 4 | 2021 | 4829 | 0.190 |
Why?
|
| Gossypol | 1 | 2021 | 28 | 0.180 |
Why?
|
| SOX9 Transcription Factor | 2 | 2019 | 178 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2023 | 2354 | 0.180 |
Why?
|
| Endogenous Retroviruses | 1 | 2020 | 43 | 0.180 |
Why?
|
| Perineum | 1 | 2021 | 115 | 0.180 |
Why?
|
| Pancreas, Exocrine | 1 | 2020 | 23 | 0.170 |
Why?
|
| Molecular Targeted Therapy | 5 | 2019 | 2390 | 0.170 |
Why?
|
| Nuclear Proteins | 4 | 2022 | 3438 | 0.170 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2019 | 361 | 0.170 |
Why?
|
| PPAR delta | 1 | 2019 | 53 | 0.170 |
Why?
|
| Benchmarking | 1 | 2021 | 275 | 0.160 |
Why?
|
| Th17 Cells | 1 | 2020 | 163 | 0.160 |
Why?
|
| Carcinoma | 2 | 2024 | 2609 | 0.160 |
Why?
|
| Treatment Outcome | 14 | 2023 | 33696 | 0.150 |
Why?
|
| Signal Transduction | 3 | 2018 | 12098 | 0.150 |
Why?
|
| Carcinosarcoma | 1 | 2019 | 146 | 0.150 |
Why?
|
| Mutation | 4 | 2020 | 15901 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2007 | 1415 | 0.140 |
Why?
|
| Pancreatitis | 1 | 2020 | 294 | 0.140 |
Why?
|
| Glycolysis | 1 | 2020 | 530 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 4784 | 0.140 |
Why?
|
| Anastomotic Leak | 1 | 2017 | 83 | 0.140 |
Why?
|
| Young Adult | 7 | 2019 | 22178 | 0.140 |
Why?
|
| Peritoneal Lavage | 1 | 2016 | 21 | 0.140 |
Why?
|
| Galectin 3 | 1 | 2017 | 131 | 0.140 |
Why?
|
| Risk Factors | 9 | 2018 | 17857 | 0.140 |
Why?
|
| Rare Diseases | 1 | 2019 | 358 | 0.140 |
Why?
|
| X-linked Nuclear Protein | 3 | 2022 | 54 | 0.130 |
Why?
|
| Gene Expression Profiling | 3 | 2023 | 5141 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 893 | 0.130 |
Why?
|
| Perfusion | 3 | 2024 | 285 | 0.130 |
Why?
|
| Cohort Studies | 8 | 2021 | 9470 | 0.130 |
Why?
|
| Co-Repressor Proteins | 3 | 2022 | 120 | 0.130 |
Why?
|
| Survival Analysis | 6 | 2018 | 9290 | 0.130 |
Why?
|
| Smad4 Protein | 1 | 2016 | 201 | 0.130 |
Why?
|
| Mitotic Index | 1 | 2015 | 162 | 0.120 |
Why?
|
| Molecular Chaperones | 3 | 2022 | 266 | 0.120 |
Why?
|
| Homeostasis | 1 | 2020 | 926 | 0.120 |
Why?
|
| Macrophages | 2 | 2020 | 1351 | 0.120 |
Why?
|
| Cholecystectomy | 1 | 2015 | 118 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2015 | 1312 | 0.120 |
Why?
|
| Prospective Studies | 8 | 2023 | 13396 | 0.120 |
Why?
|
| Cell Adhesion Molecules | 1 | 2017 | 572 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 1542 | 0.120 |
Why?
|
| Genetic Markers | 1 | 2017 | 1075 | 0.120 |
Why?
|
| Organ Specificity | 1 | 2015 | 737 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 1002 | 0.110 |
Why?
|
| Estrogen Receptor beta | 1 | 2014 | 149 | 0.110 |
Why?
|
| DNA Mutational Analysis | 2 | 2021 | 2357 | 0.110 |
Why?
|
| Patient Selection | 2 | 2021 | 2026 | 0.110 |
Why?
|
| Cell Nucleus | 1 | 2019 | 1712 | 0.110 |
Why?
|
| DNA Copy Number Variations | 4 | 2021 | 1552 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2019 | 1641 | 0.110 |
Why?
|
| Endonucleases | 1 | 2014 | 184 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2020 | 1871 | 0.110 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2013 | 37 | 0.110 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2014 | 347 | 0.110 |
Why?
|
| PAX8 Transcription Factor | 1 | 2013 | 51 | 0.110 |
Why?
|
| Mucous Membrane | 2 | 2011 | 263 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 1 | 2021 | 1457 | 0.100 |
Why?
|
| Receptor, ErbB-2 | 2 | 2020 | 2650 | 0.100 |
Why?
|
| Paired Box Transcription Factors | 1 | 2013 | 128 | 0.100 |
Why?
|
| Time Factors | 3 | 2015 | 12996 | 0.100 |
Why?
|
| Cell Differentiation | 2 | 2020 | 4117 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 1280 | 0.100 |
Why?
|
| Cytoreduction Surgical Procedures | 3 | 2024 | 510 | 0.100 |
Why?
|
| Splenic Neoplasms | 1 | 2013 | 124 | 0.100 |
Why?
|
| Inflammation | 2 | 2020 | 2516 | 0.100 |
Why?
|
| Mice | 8 | 2022 | 35574 | 0.100 |
Why?
|
| Keratins | 1 | 2013 | 340 | 0.100 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 566 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 2 | 2015 | 4479 | 0.100 |
Why?
|
| Animals | 10 | 2022 | 62012 | 0.100 |
Why?
|
| Disease Models, Animal | 5 | 2021 | 7382 | 0.100 |
Why?
|
| Cisplatin | 4 | 2023 | 2496 | 0.100 |
Why?
|
| Cell Proliferation | 4 | 2019 | 7234 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 2453 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2017 | 2421 | 0.100 |
Why?
|
| Reoperation | 1 | 2016 | 1390 | 0.090 |
Why?
|
| Genomics | 2 | 2023 | 2834 | 0.090 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 2115 | 0.090 |
Why?
|
| Lewy Body Disease | 1 | 2010 | 19 | 0.090 |
Why?
|
| Biomarkers | 3 | 2020 | 5059 | 0.090 |
Why?
|
| Estrogens | 1 | 2014 | 808 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2017 | 2269 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 2 | 2015 | 1585 | 0.090 |
Why?
|
| B7-H1 Antigen | 1 | 2017 | 1081 | 0.090 |
Why?
|
| Urogenital Neoplasms | 1 | 2011 | 115 | 0.090 |
Why?
|
| Comorbidity | 1 | 2016 | 2392 | 0.090 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 489 | 0.090 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 4326 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2018 | 2099 | 0.090 |
Why?
|
| Cancer Survivors | 1 | 2017 | 744 | 0.090 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2021 | 880 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2015 | 1260 | 0.080 |
Why?
|
| Cancer Care Facilities | 1 | 2014 | 907 | 0.080 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2015 | 743 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2020 | 6761 | 0.080 |
Why?
|
| Pancreatectomy | 1 | 2014 | 696 | 0.080 |
Why?
|
| Disease Progression | 3 | 2019 | 6851 | 0.080 |
Why?
|
| Receptors, Estrogen | 2 | 2014 | 2159 | 0.080 |
Why?
|
| Antineoplastic Agents | 5 | 2019 | 14614 | 0.080 |
Why?
|
| Peroneal Nerve | 1 | 2007 | 5 | 0.080 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 4961 | 0.080 |
Why?
|
| Melanoma | 2 | 2015 | 5594 | 0.080 |
Why?
|
| Neural Conduction | 1 | 2007 | 109 | 0.070 |
Why?
|
| Cats | 1 | 2007 | 169 | 0.070 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2007 | 3 | 0.070 |
Why?
|
| Mitomycin | 2 | 2020 | 213 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2016 | 7779 | 0.070 |
Why?
|
| Intestine, Small | 1 | 2011 | 520 | 0.070 |
Why?
|
| Pericytes | 1 | 2007 | 91 | 0.070 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2007 | 117 | 0.070 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2007 | 52 | 0.070 |
Why?
|
| Orchiectomy | 1 | 2007 | 211 | 0.070 |
Why?
|
| Paclitaxel | 3 | 2021 | 2100 | 0.070 |
Why?
|
| Transcription Factors | 3 | 2017 | 5437 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 2196 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 1266 | 0.070 |
Why?
|
| Ovariectomy | 1 | 2007 | 369 | 0.070 |
Why?
|
| Immunoglobulin A | 1 | 2007 | 271 | 0.070 |
Why?
|
| Nomograms | 2 | 2021 | 312 | 0.070 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2006 | 17 | 0.070 |
Why?
|
| DNA Repair | 1 | 2014 | 1910 | 0.070 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 3029 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2020 | 9036 | 0.070 |
Why?
|
| Schistosomiasis | 1 | 2006 | 65 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 3656 | 0.060 |
Why?
|
| Reference Values | 1 | 2007 | 1134 | 0.060 |
Why?
|
| Prevalence | 1 | 2013 | 3399 | 0.060 |
Why?
|
| Thyroid Neoplasms | 1 | 2015 | 1876 | 0.060 |
Why?
|
| Endosonography | 2 | 2017 | 551 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 2010 | 817 | 0.050 |
Why?
|
| alpha-Thalassemia | 1 | 2022 | 11 | 0.050 |
Why?
|
| Organoplatinum Compounds | 2 | 2016 | 704 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2022 | 1579 | 0.050 |
Why?
|
| Bacteria | 1 | 2007 | 653 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 4646 | 0.050 |
Why?
|
| Contraindications, Procedure | 1 | 2021 | 9 | 0.050 |
Why?
|
| Mental Retardation, X-Linked | 1 | 2022 | 105 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 5001 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2016 | 5666 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 3911 | 0.050 |
Why?
|
| Phosphoproteins | 2 | 2017 | 1137 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2023 | 315 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2007 | 1424 | 0.050 |
Why?
|
| INDEL Mutation | 1 | 2021 | 114 | 0.050 |
Why?
|
| Metallothionein | 1 | 2020 | 33 | 0.050 |
Why?
|
| Genes, APC | 1 | 2020 | 71 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2020 | 5725 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2020 | 160 | 0.040 |
Why?
|
| Immunity, Mucosal | 1 | 2020 | 121 | 0.040 |
Why?
|
| United States | 4 | 2018 | 15817 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 14825 | 0.040 |
Why?
|
| Cell Plasticity | 1 | 2020 | 67 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2022 | 450 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2020 | 181 | 0.040 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2019 | 167 | 0.040 |
Why?
|
| Ploidies | 1 | 2019 | 250 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2020 | 295 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 7096 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2020 | 628 | 0.040 |
Why?
|
| Vimentin | 1 | 2019 | 255 | 0.040 |
Why?
|
| Histone Chaperones | 1 | 2018 | 32 | 0.040 |
Why?
|
| Interleukin-17 | 1 | 2020 | 256 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2022 | 958 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 12020 | 0.040 |
Why?
|
| Celiac Artery | 1 | 2018 | 43 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2019 | 229 | 0.040 |
Why?
|
| Point Mutation | 1 | 2021 | 788 | 0.040 |
Why?
|
| Splenic Artery | 1 | 2018 | 54 | 0.040 |
Why?
|
| ral GTP-Binding Proteins | 1 | 2017 | 23 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2021 | 697 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2021 | 668 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2020 | 766 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 530 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 574 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 2359 | 0.040 |
Why?
|
| Galectins | 1 | 2017 | 73 | 0.040 |
Why?
|
| Brain | 1 | 2010 | 4212 | 0.040 |
Why?
|
| Oncogenes | 1 | 2020 | 700 | 0.040 |
Why?
|
| Contrast Media | 1 | 2024 | 1498 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 676 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2022 | 3399 | 0.040 |
Why?
|
| Laparotomy | 1 | 2018 | 234 | 0.040 |
Why?
|
| Azepines | 1 | 2017 | 134 | 0.030 |
Why?
|
| Hepatic Artery | 1 | 2018 | 256 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 553 | 0.030 |
Why?
|
| Cadherins | 1 | 2019 | 657 | 0.030 |
Why?
|
| Adolescent | 2 | 2014 | 32693 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2017 | 299 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2020 | 700 | 0.030 |
Why?
|
| Arteries | 1 | 2017 | 290 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 271 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 2016 | 201 | 0.030 |
Why?
|
| Apoptosis | 2 | 2021 | 7752 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2016 | 347 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 2308 | 0.030 |
Why?
|
| Retinal Dehydrogenase | 1 | 2015 | 85 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2020 | 1058 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 2018 | 637 | 0.030 |
Why?
|
| Propensity Score | 1 | 2018 | 768 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2018 | 526 | 0.030 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2015 | 153 | 0.030 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2016 | 275 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2021 | 1012 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2846 | 0.030 |
Why?
|
| Japan | 1 | 2014 | 236 | 0.030 |
Why?
|
| Cell Aggregation | 1 | 2013 | 61 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2015 | 929 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2014 | 205 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2019 | 1958 | 0.030 |
Why?
|
| Triazoles | 1 | 2017 | 627 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2021 | 1207 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 1401 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 5403 | 0.030 |
Why?
|
| Drug Approval | 1 | 2014 | 174 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2017 | 839 | 0.030 |
Why?
|
| Nervous System | 1 | 2013 | 183 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 266 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2015 | 651 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2014 | 351 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 676 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2021 | 2165 | 0.030 |
Why?
|
| Child | 1 | 2014 | 30500 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2014 | 437 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2015 | 440 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2019 | 4329 | 0.030 |
Why?
|
| Taxoids | 1 | 2016 | 1015 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2020 | 5694 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2014 | 806 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2015 | 427 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 632 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 1017 | 0.020 |
Why?
|
| Cell Survival | 1 | 2017 | 3059 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2014 | 1247 | 0.020 |
Why?
|
| Liver | 1 | 2021 | 3086 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2018 | 912 | 0.020 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2010 | 14 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2018 | 2245 | 0.020 |
Why?
|
| Neurofibrillary Tangles | 1 | 2010 | 28 | 0.020 |
Why?
|
| Synaptophysin | 1 | 2010 | 83 | 0.020 |
Why?
|
| Histones | 1 | 2018 | 1512 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2015 | 1989 | 0.020 |
Why?
|
| Neurites | 1 | 2010 | 70 | 0.020 |
Why?
|
| Survivors | 1 | 2016 | 1022 | 0.020 |
Why?
|
| Fibrosis | 1 | 2013 | 733 | 0.020 |
Why?
|
| Plaque, Amyloid | 1 | 2010 | 63 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 4223 | 0.020 |
Why?
|
| Tissue Fixation | 1 | 2010 | 137 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2010 | 223 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2014 | 1164 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2014 | 692 | 0.020 |
Why?
|
| Presynaptic Terminals | 1 | 2010 | 121 | 0.020 |
Why?
|
| Decision Making | 1 | 2017 | 1249 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 1341 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 1099 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 965 | 0.020 |
Why?
|
| alpha-Synuclein | 1 | 2010 | 118 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 16182 | 0.020 |
Why?
|
| Portal Vein | 1 | 2011 | 363 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 1742 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 4134 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 1709 | 0.020 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2015 | 1094 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 1564 | 0.020 |
Why?
|
| Biopsy | 1 | 2015 | 3482 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 5459 | 0.020 |
Why?
|
| Bacterial Vaccines | 1 | 2007 | 118 | 0.020 |
Why?
|
| CD40 Antigens | 1 | 2007 | 106 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2010 | 630 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2017 | 2929 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2007 | 170 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2015 | 2376 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2010 | 1145 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 6503 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 6190 | 0.020 |
Why?
|
| Travel | 1 | 2006 | 202 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2014 | 6397 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2013 | 6238 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 3843 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2016 | 3662 | 0.010 |
Why?
|
| Intestines | 1 | 2007 | 735 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2007 | 1052 | 0.010 |
Why?
|
| Acute Disease | 1 | 2006 | 2494 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2007 | 1110 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 5775 | 0.010 |
Why?
|
| Base Sequence | 1 | 2007 | 5437 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 6686 | 0.010 |
Why?
|
| Cytokines | 1 | 2007 | 2826 | 0.010 |
Why?
|